title: Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
abstract: Vascular events commonly recur in stroke patients on aspirin, and may reflect incomplete inhibition of platelet function with aspirin therapy. The platelet function analyser (PFA-100) activates platelets by aspirating a blood sample at a moderately high shear rate through a capillary to a biologically active membrane with a central aperture. The membrane is coated with collagen, and either ADP (C-ADP) or epinephrine (C-EPI). The time taken for activated platelets to adhere, aggregate, and occlude the aperture is called the closure time. Previous studies have shown that aspirin prolongs the C-EPI closure time, without prolongation of the C-ADP closure time, in the majority of control subjects. We hypothesised that the PFA-100 would provide a sensitive assay for the detection of early and convalescent phase cerebrovascular disease (CVD) patients who had incomplete inhibition of platelet function with aspirin. We investigated potential cyclooxygenase-dependent and -independent mechanisms that might influence the responsiveness to aspirin using the PFA-100. Patients were studied during the early (< or = 4 weeks, n=57) and convalescent phases ((< or = 3 months, n=46) after ischaemic stroke or TIA. To investigate potential mechanisms that could contribute to aspirin responsiveness on the PFA-100, we measured von Willebrand factor antigen levels, and carried out platelet aggregometry experiments in platelet-rich plasma in response to sodium arachidonate (1 mM) and ADP (5 microM). Sixty percent of patients in the early phase and 43% of patients in the convalescent phase did not have prolonged C-EPI closure times on 75-300 mg of aspirin daily, and were defined as aspirin non-responders. Median C-ADP closure times were significantly shorter in aspirin non-responders than aspirin-responders in both the early and convalescent phases after symptom onset (P=0.008), suggesting platelet hyper-reactivity to collagen or ADP in the aspirin non-responder subgroup. There was a significant inverse relationship between plasma von Willebrand factor antigen levels and C-EPI closure times in both early and convalescent phase CVD patients (P=0.008). Mean von Willebrand factor antigen levels were significantly higher in aspirin non-responders than aspirin responsive patients in the early (P=0.001), but not convalescent phase (P=0.2) after stroke and TIA. None of the patients studied were defined as being aspirin-resistant using sodium arachidonate- or ADP-induced platelet aggregometry. A large proportion of ischaemic CVD patients have incomplete inhibition of platelet function with low to medium dose aspirin using the PFA-100. The results suggest that cyclooxygenase-independent mechanisms, including elevated von Willebrand factor antigen levels, play an important role in mediating aspirin non-responsiveness on the PFA-100.
authors: The Haemostasis Research Unit, Department of Haematology.
authors: Dominick J H
authors: DJ
authors: McCabe
authors: Paul
authors: P
authors: Harrison
authors: Ian J
authors: IJ
authors: Mackie
authors: Paul S
authors: PS
authors: Sidhu
authors: Andrew S
authors: AS
authors: Lawrie
authors: Gordon
authors: G
authors: Purdy
authors: Samuel J
authors: SJ
authors: Machin
authors: Martin M
authors: MM
authors: Brown
mesh_terms: D000244:Adenosine Diphosphate / Q000097:blood / Q000494:pharmacology; D000368:Aged; D016718:Arachidonic Acid / Q000097:blood / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D016022:Case-Control Studies; D016861:Cyclooxygenase Inhibitors / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010979:Platelet Function Tests; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D020521:Stroke / Q000097:blood* / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin; D004837:Epinephrine